Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3025–3048 of 21,430 matching trials from the live ClinicalTrials.gov search.
Conditions
Non-Small Cell Lung Cancer
Interventions
Docetaxel/Carboplatin/Bevacizumab/Erlotinib, Docetaxel/Carboplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
26
States / cities
Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 20 more
Conditions
Thymoma
Interventions
BKM120
Drug
Lead sponsor
Patrick Joseph Loehrer Sr.
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Giant Cell Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Stage IIIB Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma
Interventions
Quemliclustat, Biospecimen Collection, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab, Biopsy Procedure
Drug · Procedure · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Triple-negative Breast Cancer
Interventions
Breast surgery, Magnetic resonance imaging, Mammography
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
179
States / cities
Gilbert, Arizona • Jonesboro, Arkansas • Antioch, California + 141 more
Conditions
Esophageal Neoplasm
Interventions
UFT (Tegafur/Uracil)
Drug
Lead sponsor
Edelman, Martin, M.D.
Individual
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions
Busulfan, Clofarabine, Allogeneic Stem Cell Infusion
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Carcinoma, Pancreatic Ductal, Pancreatic Cancer, Pancreatic Disease
Interventions
AGS-1C4D4, Gemcitabine
Biological
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
La Jolla, California • Boynton Beach, Florida • Miami, Florida + 12 more
Conditions
Multiple Myeloma, Refractory
Interventions
Pembrolizumab, Belantamab mafodotin, Dexamethasone
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey • Neptune City, New Jersey
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Interventions
oral rigosertib, Azacitidine
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
12
States / cities
Gilbert, Arizona • Duarte, California • Rancho Mirage, California + 9 more
Completed Phase 1Phase 2 Interventional Results available

MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia

NCT03008187
Conditions
Acute Myeloid Leukemia
Interventions
MEN1703
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Atlanta, Georgia • Cleveland, Ohio • Portland, Oregon + 4 more
Conditions
Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm
Interventions
Cognitive Assessment, Stereotactic Radiosurgery, Stereotactic Body Radiation Therapy, Quality-of-Life Assessment
Procedure · Radiation · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
2
States / cities
Sewell, New Jersey • Philadelphia, Pennsylvania
Conditions
Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Estrogen Receptor-positive, HER2/Neu Negative
Interventions
Atezolizumab, Cobimetinib, Idasanutlin
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Gastrointestinal Cancer, Carcinoma, Neuroendocrine
Interventions
Cisplatin, Irinotecan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Cancer
Interventions
doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Peripheral Artery Disease, Ischaemic Ulcer of Lower Leg Due to Atherosclerotic Disease, Chronic Limb Threatening Ischemia, Ischemic Ulcer of Foot
Interventions
AMG0001, Placebo
Biological
Lead sponsor
AnGes USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
20
States / cities
Carlsbad, California • Downey, California • Fresno, California + 16 more
Conditions
Sarcoma
Interventions
cidofovir
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Metastatic Triple-Negative Breast Cancer
Interventions
Trilaciclib, Pembrolizumab, Gemcitabine, Carboplatin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Charlotte, North Carolina
Conditions
Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma, Paraganglioma, Thymus Carcinoid, Unknown Primary Tumors, Neuroendocrine Tumors, Neuroendocrine Skin Carcinoma, Neuroendocrine Breast Tumor, Neuroendocrine Carcinoma Metastatic, Neuroendocrine Neoplasm of Ovary
Interventions
177Lu-DOTATOC
Drug
Lead sponsor
Excel Diagnostics and Nuclear Oncology Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Conditions
Kidney Cancer
Interventions
INC280
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Recurrent Non-small Cell Lung Cancer
Interventions
cediranib maleate, pemetrexed disodium
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
2
States / cities
Baltimore, Maryland • Detroit, Michigan
Conditions
Ulcerative Colitis
Interventions
Andecaliximab, Placebo
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
33
States / cities
Dothan, Alabama • Wheat Ridge, Colorado • Lauderdale Lakes, Florida + 30 more
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Stage I Colorectal Cancer, Stage II Colorectal Cancer, Stage III Colorectal Cancer
Interventions
Not listed
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Non-small Cell Lung Cancer
Interventions
fianlimab, cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
29
States / cities
Tucson, Arizona • Yuma, Arizona • Cerritos, California + 24 more
Conditions
Hematopoietic Stem Cell Transplantation
Interventions
CD3+ T cell depletion
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama